CD105与肿瘤关系的研究进展

Research progress in CD105 and its relation with tumors

CD105(Endoglin)是血管内皮标记,已成为抗癌治疗研究中的热点。CD105是转化生长因子-β(transforming growth factor-β,TGF-β)家族受体蛋白,主要在血管内皮细胞表达,亦是调节细胞对TGF-β的反应成分之一。CD105主要在胚胎形成和恶性肿瘤表达较高,主要表达在肿瘤的血管。CD105标记的微血管密度(microvessel density,MVD)是一个独立的预后指标,同时MVD的数目和生存率成反比,故可能成为肿瘤诊断、发生发展及其预后的新指标。CD105与以往泛血管内皮标记因子相比,是一种较佳的新生血管生成标志,似可作为衡量血管内皮细胞增殖状态的指标之一。以CD105为靶分子判断恶性肿瘤发生发展与研究肿瘤预后可望成为一种有前途的方法。

CD105 （Endoglin） is a vessel endothelial cell marker and has been a hot spot in anti-cancer therapy. CD105 is a family receptor protein of transforming growth factor-β（TGF-β）, mainly expresses in vessel endothelial cells adjusting the reaction of cells to TGF-β. CD105 mainly expresses in vessel endothelial cells in connnective tissue and tumor tissue. Immunohistochemistry studies have revealed that CD105 is strongly expressed in blood vessels of tumor tissues. Intratumoral microvessel density （MVD） determined by using antibodies to CD105 has been found to be an independent prognostic indicator, wherein increased MVD correlates with shorter survival, and it has been recognized as a promising vascular target. Compared to the past endothelial growth factors, CD105 is a better vessel endothelial cell marker factor, and it may be a new symbol and can be used as a new index for diagnosis and prognosis of tumor. It will be a useful method to estimate the progress and prognosis while using CD105 as a target molecule.